This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.
Principal Investigator
Anne-Marie Langevin
Patient must have a lifetime cumulative anthracycline dose of >= 250 mg/m^2 DOXOrubicin equivalent without the protection of dexrazoxane (Zinecard) therapy; the anthracycline dose threshold must be met as part of the treatment of a cancer that was diagnosed at < 22 years of age
Ejection fraction of < 50% (by radionuclide angiogram or echocardiogram) or shortening fraction of < 25% (by echocardiogram)
Uncorrected primary obstructive or severe regurgitative valvular disease:
Arm | Description | Intervention |
---|---|---|
Arm II (placebo) | Patients receive placebo PO QD or BID for 24 months. | Correlative studies Correlative studies Ancillary studies Other names:
Correlative studies Other names:
Given PO Ancillary studies |
Arm I (carvedilol) | Patients receive low-dose carvedilol PO QD or BID for 24 months. | Correlative studies Correlative studies Ancillary studies Other names:
Given PO Other names:
Correlative studies Other names:
Ancillary studies |